As disheartening as it can be to experience treatment that does not do all that we need it to or have dear ones who do not respond to current melanoma treatments - therapies for melanoma have come a long way, baby!!!! Not only are more folks than ever before responding to therapy - these responses are proving durable! Here are some outcome studies ~
Five-year overall survival from the anti-PD1 brain
collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or
nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases
(mets). Georgina V. Long, Victoria
Atkinson, Serigne Lo, et al. ASCO 2021.
Background:
Preliminary data from the ABC (76 pts) and CheckMate 204 (94 pts) trials
showed that nivo and nivo+ipi have activity in active melanoma brain
metastases, with durable responses in a subset of pts. Here, we report updated
5-yr data from all pts enrolled on the ABC trial (NCT02374242).
Methods: This
open-label ph2 trial enrolled 3 cohorts of pts with active melanoma brain mets
naïve to anti-PD1/PDL1/PDL2/CTLA4 from Nov 2014-Apr 2017. Pts with asymptomatic
brain mets with no prior local brain therapy were randomised to cohort A (nivo
1mg/kg + ipi 3mg/kg, Q3Wx4, then nivo 3mg/kg Q2W) or cohort B (nivo 3mg/kg
Q2W). Cohort C (nivo 3mg/kg Q2W) had brain mets i) that failed local therapy,
ii) with neuro symptoms and/or iii) with leptomeningeal disease. Prior BRAF
inhibitor (BRAFi) was allowed. The primary endpoint was best intracranial
response (ICR) ≥wk12. Key secondary endpoints were IC PFS, overall PFS, OS,
& safety.
Results: A total of 76 pts (med f/u 54 mo) were enrolled;
median age 59y, 78% male. For cohorts A, B and C: elevated LDH 51%, 58% and
19%; V600BRAF 54%, 56% and 81%; prior BRAFi 23%, 24%, 75%. Efficacy and
toxicity are shown in the table. There were no treatment-related deaths. 1/17
deaths in cohort A & 4/16 in cohort B were due to IC progression only.
Conclusions: Nivo
monotherapy and ipi+nivo are active in melanoma brain mets, with durable
responses in the majority of patients who received ipi+nivo upfront. A study of
upfront ipi+nivo+/-SRS is underway (NCT03340129).Clinical trial information:
NCT02374242.
My takeaway - Immunotherapy works for brain mets! BUT - most folks need the combo!!!!
As was mentioned briefly in yesterday's post - the ipi/nivo combo can be a rough road in regard to side effects and a good 40% of patients cannot tolerate all of the approved doses. However, as far back ASCO 2016 we knew that folks who had to stop therapy early due to side effects, responded about as well as those who completed all doses: ASCO 2016 - Nivo plus ipi, CheckMate 069 trial....18 month OS similar even if you stop meds due to side effects!!! This study wanted to see if those responses were durable ~
Survival outcomes associated with fewer combination
ipilimumab/nivolumab doses in advanced-stage melanoma. Ma, Sun, Sitto, et al. ASCO 2021.
Background: Standard
combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for
advanced stage melanoma. While many patients receive less than 4 doses due to
treatment-related toxicities, it is unclear if fewer doses of I/N may still
provide long term clinical benefit. Our aim is to determine if response
assessment after 1 or 2 doses of I/N can predict long-term survival and if
fewer doses of I/N can achieve similar survival outcomes.
Methods: We performed
a single-center, retrospective analysis on a cohort of patients with metastatic
or unresectable melanoma from 2012 to 2020 who were treated with standard I/N.
Cox regression of progression free survival (PFS) and overall survival (OS)
models were performed to assess the relationship between response assessment
after 1 or 2 doses of I/N and risk of progression and/or death. Clinical
benefit response (CBR) was assessed, defined as SD (stable disease) + PR
(partial response) + CR (complete response) by imaging or physical examination.
Among patients who achieved a CBR after 1 or 2 doses of I/N, a multivariable
Cox regression of survival was used to compare 3 or 4 vs 1 or 2 doses of I/N
adjusted by age, gender, pre-treatment LDH level, BRAF mutation status, primary
melanoma site, time to initial assessment, brain metastasis, and liver metastasis.
Results: 199 patients
were identified and considered evaluable in our study. Median follow up was
28.8 months. Patients with CBR after 1 dose of I/N had improved PFS and OS
compared to progressive disease (PD). Patients with CBR (vs PD) after 2 doses
of I/N also had improved PFS and OS. The survival risk comparing 3 or 4 vs 1 or
2 doses of I/N were HR 0.82 for PFS and HR 0.56 for OS.
Conclusions: Clinical
benefit response (CBR) after 1 or 2 doses of I/N may be predictive of long-term
survival in advanced stage melanoma. Patients who have CBR after 1 or 2 doses
of I/N may achieve a similar survival benefit with fewer doses of I/N. Longer
follow up and prospective studies are warranted to validate our findings.
Per this report, it looks as though those who showed benefit to therapy early, did indeed have similar survival, even when they took fewer that the 4 recommended combo doses!
This study looked at the characteristics of peeps who lived 5 years past immunotherapy for melanoma ~
Characteristics and probability of survival for
patients with advanced melanoma who live five or more years after initial
treatment with immune checkpoint blockade (ICB). Loo, Goldman, Panageas, …Chapman…Wolchok…Postow,
et al. ASCO 2021.
Methods: We
retrospectively reviewed all patients treated at Memorial Sloan Kettering for
unresectable stage III/IV melanoma who survived at least five years following
their first dose of ICB (N = 151). Demographics, disease characteristics, and
nature of progression were examined. Overall survival (OS) was calculated from
5 years post-ICB. Time to Treatment failure (TTF) was calculated conditionally
from 5 years out until next therapy, progression, or death.
Results: Of the 151
long-term survivors, median age at first ICB treatment was 62 years (range
22-83), with 101 (66.9%) male and 50 (33.1%) female patients. Stage at first
ICB treatment was unresectable stage III (26, 17.2%), M1a (21,13.9%), M1b (39,
25.8%), M1c (52, 34.4%), M1d (13, 8.6%). Melanoma subtype was cutaneous (122,
80.8%), unknown primary (24, 15.9%), mucosal (3, 2%), and acral (2, 1.3%).
First ICB was ipi (108, 71.5%), PD-1 (nivo or pembro) (5, 3.3%), and nivo+ipi
(37, 24.5%). The best overall response to first ICB was CR (76, 50.3%), PR (27,
17.9%), SD (16, 10.6%) and PD (32, 21.2%). Of the patients who progressed after
initial ICB, 38 received subsequent systemic treatment as follows: PD-(L)1 in
20 (53%), BRAF ± MEK in 9 (23.7%), ipi in 7 (18.4%), and chemotherapy in 2
(5.3%). Median duration of follow-up among survivors (N = 138) was 93 months
(range 60-192). From 5 years post-ICB, 85% (95% CI: 73-92%) survived an
additional 5 years. In those who made it to 5 years without treatment failure
(N = 72), the probability of remaining failure-free was 92% (95% CI: 86-99%) at
7 years. Of the 151 patients, only 4 patients (2.6%) experienced disease
progression after 5 years. Three patients had radiographic or pathologic
disease progression in the lymph nodes and one in the subcutaneous tissue. No
patients progressed in the lungs, visceral organs, or CNS after 5 years. At
time of analysis, 13 (8.6%) patients died after 5 years post ICB, none died of
progressive melanoma. 6 patients died of unknown causes, 2 died of other
causes, and 5 died of other non-melanoma cancer-related causes.
Conclusions: Patients
who survive five years after their initial immunotherapy have excellent overall
survival and treatment failure-free survival. Given the anxiety surrounding
survivorship and late progression, long-term survivors should be reassured of
their excellent prognosis. These data suggest that aggressive follow-up
schedules and imaging of melanoma patients after 5 years of survival may not be
required.
WHOOP! WHOOP!!! The C-word (NO! Not cancer! CURE!!) was not used, but this data on peeps 5 years out who may no longer need scans to follow up and can carry on with their lives is AWESOME! On a personal note, Weber let me off the hook for continued follow-up for melanoma at 8 years post my Stage IV diagnosis. I am currently 11 years out.
This study looked at peeps treated with nivo alone vs the ipi/nivo combo. Now we are blessed to look at 6.5 year outcomes. These reports would not exist without the lives and dedication of all the ratties; and sometimes a special mouse!!! Thanks, Edster!!!!
CheckMate 067: 6.5-year outcomes in patients (pts)
with advanced melanoma. Wolchok, Chiarion-Sileni, Gonzalez, et al. ASCO 2021.
Background: In the phase 3 CheckMate 067 trial, a durable
and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab
(IPI) and NIVO alone vs IPI at 5-y of follow-up (overall survival [OS] and
progression-free survival [PFS] rates: 52%, 44%, 26% and 36%, 29%, 8%, respectively).
Here we report 6.5-y efficacy and safety outcomes.
Methods: Eligible pts
with previously untreated unresectable stage III or IV melanoma were randomly
assigned in a 1:1:1 ratio and stratified by PD-L1 status, BRAF mutation status,
and metastasis stage. Pts received NIVO 1 mg/kg + IPI 3 mg/kg for 4 doses Q3W
followed by NIVO 3 mg/kg Q2W (n = 314), NIVO 3 mg/kg Q2W + placebo (n = 316),
or IPI 3 mg/kg Q3W for 4 doses + placebo (n = 315) until progression or
unacceptable toxicity. Co-primary endpoints were PFS and OS with NIVO + IPI or
NIVO vs IPI. Secondary endpoints included objective response rate (ORR),
descriptive efficacy assessments of NIVO + IPI vs NIVO alone, and safety.
Results: With a
minimum follow-up of 6.5 y, median OS was 72.1 mo with NIVO + IPI, 36.9 mo with
NIVO, and 19.9 mo with IPI (table). Median time from randomization to
subsequent systemic therapy was not reached with NIVO + IPI, 25.2 mo with NIVO,
and 8.0 mo with IPI; 36%, 49%, and 66% of pts, respectively, received any
subsequent systemic therapy. Median treatment-free interval (which excluded pts
who discontinued follow-up prior to initiation of subsequent systemic therapy)
was 27.6 mo (range, 0–83.0), 2.3 mo (range, 0.2–81.6), and 1.9 mo (range,
0.1–81.9) with NIVO + IPI, NIVO, and IPI, respectively. Of the pts alive and in
follow-up, 112/138 (81%; NIVO + IPI), 84/114 (74%; NIVO), and 27/63 (43%; IPI)
were off treatment and never received subsequent systemic therapy; 7, 8, and 0
pts, respectively, were still on treatment. Grade 3/4 treatment-related adverse
events were reported in 59% of NIVO + IPI-treated pts, 24% of NIVO-treated pts,
and 28% of IPI-treated pts. Since the 5-y analysis, no new safety signals were
observed and no additional treatment-related deaths occurred.
Conclusions: This
6.5-y analysis represents the longest follow-up from a phase 3 melanoma trial
in the modern checkpoint inhibitor combination therapy and targeted therapy
era. The results show durable improved outcomes with NIVO + IPI and NIVO vs IPI
in pts with advanced melanoma. We observed improvement in OS, PFS, and ORR with
NIVO + IPI over NIVO alone. Clinical trial information: NCT01844505.
My takeaway - AGAIN - though nivo alone works for many (look at me!!) - BUT - data shows responses and durability were better with the ipi/nivo combo. Way to rock it out, ratties!! Thanks, dear Ed!
Finally, a non-ASCO report from earlier this year looking at folks who chose to stop anti-PD-1 monotherapy with nivo (Opdivo) or pembro (Keytruda) at 1 year of therapy ~
Real-world experience with elective discontinuation of
PD-1 inhibitors at 1 year in patients with metastatic melanoma. Pokorny, McPherson, Haaland, et al. J Immunother Cancer. Jan 2021.
Background: Randomized trials evaluating programmed cell
death protein 1 (PD-1) inhibitors in metastatic melanoma either permitted
treatment for 2 years (pembrolizumab) or more (nivolumab). The optimal duration
of therapy is currently unknown due to limited data, and shorter therapies may
be effective.
Methods: Data of patients with metastatic cutaneous melanoma
treated with single-agent PD-1 inhibitors at Huntsman Cancer Institute from January
1, 2015, to December 31, 2018, was reviewed to identify a continuous series of
patients who made the joint decision with their provider to electively
discontinue therapy at 1 year (greater than 6 months and less than 18 months) in the setting
of ongoing treatment response or disease stability. Patients were excluded if
they received PD-1 inhibitors with other systemic therapy, had prior exposure
to PD-1 therapy, or discontinued treatment due to disease progression or
immune-related adverse event. Best objective response (BOR) per RECIST V.1.1 at
treatment discontinuation, progression-free survival (PFS), and retreatment
characteristics was analyzed.
Results: Of 480 patients who received PD-1 inhibitors, 52
met the inclusion criteria. The median treatment duration from first to the
last dose was 11.1 months (95% CI 10.5 to 11.4). BOR was complete response in
13 (25%), partial response in 28 (53.8%), and stable disease in 11 (21.2%)
patients. After a median follow-up of 20.5 months (range 3-49.2) from treatment
discontinuation, 39 (75%) patients remained without disease progression, while
13 (25%) had progression (median PFS 3.9 months; range 0.7-30.9). On
multivariable analysis, younger age, history of brain metastasis, and higher
lactate dehydrogenase at the time of anti-PD-1 discontinuation were associated
with recurrence. Patients with recurrent melanoma were managed with localized
treatment, anti-PD-1 therapies, and BRAF-MEK inhibitors. All patients except
one were alive at data cutoff.
Conclusion: In this large real-world, observational cohort
study, the majority of patients with metastatic melanoma after 1 year of
anti-PD-1 therapy remained without progression on long-term follow-up. The risk
of disease progression even in patients with residual disease on imaging was low.
After prospective validation, elective PD-1 discontinuation at 1 year may
reduce financial and immunotherapy-related toxicity without sacrificing
outcomes.
In my 2010, nivo as a single agent, phase 1 study, we took nivo for 2 1/2 years on a rather different schedule than is utilized currently (every 2 weeks for 6 months, then every 3 months for 2 years) and at dosages of 1mg/kg (my cohort), 3 mg/kg, and 10 mg/kg. The 3mg/kg dosage is basically what is used today. Still, even with all that, Weber often said that he felt we were treated too long and explained that while a certain amount of drug would be helpful, beyond that, benefit was nil and the risk of side effects was increased. Today - whether we are looking at anti-PD-1 as a single agent or the ipi/nivo combo - researchers are still trying to figure out exactly what that "certain amount" is. It is likely that the answer may vary person to person. As this study pointed out, the ratties who elected to stop therapy at one year had experienced treatment response or stable disease. Clearly, that is an important factor. Additionally, in this rather small study of 52 patients, recurrence was associated with those who were younger, had a history of brain mets and elevated LDH when therapy ceased. Interesting, in that I was 39 at diagnosis and 46 with brain mets at the start of my trial. However, I took nivo for 2 1/2 years, never had an elevated LDH and have yet to have a melanoma recurrence. So many variables. So many different peeps. It is a hard road to walk, much less to predict.
Hang tough, guys. There is hope! - c
